Sarepta Therapeutics Inc
SRPT24.450USD
+0.440+1.83%
Cierre 11/03, 16:00（ET）Cotizaciones retrasadas 15 min
2.39BCap. mercado
PérdidaP/E TTM
Más Datos de Sarepta Therapeutics Inc Compañía
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
Información de Sarepta Therapeutics Inc
Símbolo de cotizaciónSRPT
Nombre de la empresaSarepta Therapeutics Inc
Fecha de salida a bolsaJun 04, 1997
Director ejecutivoMr. Douglas S. (Doug) Ingram, Esq., J.D.
Número de empleados1372
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 04
Dirección215 First Street
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142
Teléfono16172744000
Sitio Webhttps://www.sarepta.com/
Símbolo de cotizaciónSRPT
Fecha de salida a bolsaJun 04, 1997
Director ejecutivoMr. Douglas S. (Doug) Ingram, Esq., J.D.
Ejecutivos de Sarepta Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
201.48K
+249.76%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
189.46K
+315.61%
Mr. Ryan Wong
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
136.20K
+686.03%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
Ms. Cristin L. Rothfuss
Ms. Cristin L. Rothfuss
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
--
--
Ms. Deirdre Connelly
Ms. Deirdre Connelly
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
201.48K
+249.76%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
189.46K
+315.61%
Mr. Ryan Wong
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
136.20K
+686.03%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
Por negocioUSD
Nombre
Ganancia
Proporción
ELEVIDYS
281.85M
54.93%
PMO Products
231.27M
45.07%
collaboration and other
97.97M
19.09%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
484.77M
94.48%
Rest of World
28.35M
5.52%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
ELEVIDYS
281.85M
54.93%
PMO Products
231.27M
45.07%
collaboration and other
97.97M
19.09%
Estadísticas de accionistas
Actualizado: sáb., 1 de nov
Actualizado: sáb., 1 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.17%
BlackRock Institutional Trust Company, N.A.
9.40%
D. E. Shaw & Co., L.P.
4.83%
State Street Investment Management (US)
4.49%
Two Sigma Investments, LP
3.96%
Otro
67.15%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.17%
BlackRock Institutional Trust Company, N.A.
9.40%
D. E. Shaw & Co., L.P.
4.83%
State Street Investment Management (US)
4.49%
Two Sigma Investments, LP
3.96%
Otro
67.15%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
31.26%
Investment Advisor/Hedge Fund
20.40%
Hedge Fund
20.05%
Research Firm
5.54%
Individual Investor
4.67%
Bank and Trust
1.24%
Pension Fund
1.13%
Sovereign Wealth Fund
0.90%
Insurance Company
0.03%
Otro
14.78%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
1017
84.37M
80.60%
-20.51M
2025Q2
1032
95.91M
98.15%
-10.95M
2025Q1
1077
102.36M
104.40%
-6.43M
2024Q4
1057
102.62M
105.91%
-1.51M
2024Q3
1027
96.14M
100.83%
-6.90M
2024Q2
997
94.21M
99.66%
-1.44M
2024Q1
932
88.31M
94.10%
-6.68M
2023Q4
926
87.42M
93.47%
-6.42M
2023Q3
916
88.86M
95.27%
-4.43M
2023Q2
931
87.46M
93.91%
-4.38M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
10.64M
10.17%
+1.51M
+16.51%
Aug 29, 2025
BlackRock Institutional Trust Company, N.A.
9.84M
9.4%
+937.08K
+10.53%
Jun 30, 2025
D. E. Shaw & Co., L.P.
5.06M
4.83%
+581.27K
+12.98%
Jul 18, 2025
State Street Investment Management (US)
4.70M
4.49%
+626.55K
+15.40%
Jun 30, 2025
Two Sigma Investments, LP
4.15M
3.96%
+3.31M
+397.77%
Jun 30, 2025
Barry (Richard J)
3.21M
3.07%
+32.60K
+1.02%
May 16, 2025
Wellington Management Company, LLP
2.53M
2.42%
-116.16K
-4.39%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.88M
1.79%
+55.08K
+3.02%
Jun 30, 2025
Erste Asset Management GmbH
1.62M
1.55%
+560.35K
+52.81%
Jun 30, 2025
Qube Research & Technologies Ltd
1.60M
1.53%
+1.57M
+4909.63%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: lun., 6 de oct
Actualizado: lun., 6 de oct
Nombre
Proporción
First Trust NYSE Arca Biotechnology Index Fund
3.25%
iShares Neuroscience and Healthcare ETF
1.62%
Invesco S&P SmallCap Health Care ETF
1.21%
Global X Genomics & Biotechnology ETF
1.11%
Virtus LifeSci Biotech Products ETF
0.81%
Invesco S&P SmallCap 600 Pure Growth ETF
0.66%
SPDR S&P Biotech ETF
0.65%
WisdomTree BioRevolution Fund
0.43%
Direxion Daily S&P Biotech Bull 3X Shares
0.4%
VanEck Biotech ETF
0.35%
Ver más
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.25%
iShares Neuroscience and Healthcare ETF
Proporción1.62%
Invesco S&P SmallCap Health Care ETF
Proporción1.21%
Global X Genomics & Biotechnology ETF
Proporción1.11%
Virtus LifeSci Biotech Products ETF
Proporción0.81%
Invesco S&P SmallCap 600 Pure Growth ETF
Proporción0.66%
SPDR S&P Biotech ETF
Proporción0.65%
WisdomTree BioRevolution Fund
Proporción0.43%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.4%
VanEck Biotech ETF
Proporción0.35%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
